Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05330858 · ClinicalTrials.gov registry record · Phase 1
Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy Participants
A Phase 1 study of Pharmacokinetics, sponsored by Alumis.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT05330858: Completed Phase 1 study of Pharmacokinetics, sponsored by Alumis.
NCT05330858 is a Phase 1 study of Pharmacokinetics that has completed, run by Alumis. The registered enrollment target is 14 participants, below the 62-participant average among 37 other Pharmacokinetics trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05330858, a Phase 1 study of Pharmacokinetics, has completed, sponsored by Alumis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single-center, in-house, open-label, crossover study in 15 healthy participants.
Primary Outcome
Relative bioavailability and food effect assessment via collection and comparison of PK plasma samples between dosing arms
Conditions Studied
Interventions
- DRUG ESK-001
- DRUG Rabeprazole
Study Locations (1)
California
- Alumis Central Site - Glendale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2022-03-17 |
| Est. Completion | 2022-09-20 |
| Phase | Phase 1 |
What the finished NCT05330858 record still lists
NCT05330858 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 62-participant average among 37 other Pharmacokinetics trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Pharmacokinetics appearing as the primary indexed condition, and to 2 interventions - of which ESK-001 is the first listed.
NCT05330858 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05330858 about?
NCT05330858 is a clinical study titled "Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy Participants". This is a single-center, in-house, open-label, crossover study in 15 healthy participants.
What is the current status of trial NCT05330858?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2022-03-17. Estimated completion is 2022-09-20.
What conditions does trial NCT05330858 study?
This clinical trial studies the following conditions: Pharmacokinetics.
What interventions are being tested in trial NCT05330858?
The interventions under investigation include: ESK-001 (DRUG), Rabeprazole (DRUG).
Who is sponsoring clinical trial NCT05330858?
This trial is sponsored by Alumis, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05330858 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pharmacokinetics
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05330858's enrollment target sits among peer trials
14 30th of 37 higher than 7 of 37 other Pharmacokinetics trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pharmacokinetics trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
High Potency Cannabis: Acute and Protracted Effects
RECRUITING · Phase 1
-
Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose
RECRUITING · Phase 1
-
Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)
RECRUITING · Phase 1
-
Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination
RECRUITING · Phase 1
-
A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Healthy Adult Subjects
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy